688176 亚虹医药
已收盘 01-13 15:00:01
资讯
新帖
简况
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
证券之星 · 01-11 04:28
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
证券之星 · 01-08
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
智通财经 · 01-08
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
证券之星 · 01-02
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
证券之星 · 2025-12-30
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理
证券之星 · 2025-12-28
每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理
亚虹医药：陈宝华正式履职董事会秘书
证券之星 · 2025-12-21
亚虹医药：陈宝华正式履职董事会秘书
亚虹医药：APLD-2304申报欧洲医疗器械注册获接收
证券之星 · 2025-12-21
亚虹医药：APLD-2304申报欧洲医疗器械注册获接收
亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准
智通财经 · 2025-12-17
亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准
亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司
证券之星 · 2025-12-12
亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司
【机构调研记录】淳厚基金调研亚虹医药
证券之星 · 2025-12-12
【机构调研记录】淳厚基金调研亚虹医药
亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司
证券之星 · 2025-12-11
亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司
亚虹医药(688176.SH)在ECC发布APL-1401Ⅰb期临床试验相关数据
智通财经 · 2025-12-03
亚虹医药(688176.SH)在ECC发布APL-1401Ⅰb期临床试验相关数据
亚虹医药（688176）披露变更签字注册会计师公告，11月28日股价上涨0.1%
证券之星 · 2025-11-28
亚虹医药（688176）披露变更签字注册会计师公告，11月28日股价上涨0.1%
亚虹医药：11月27日召开业绩说明会，投资者参与
证券之星 · 2025-11-27
亚虹医药：11月27日召开业绩说明会，投资者参与
亚虹医药涨5.10%，太平洋二个月前给出“买入”评级，目标价15.68元
证券之星 · 2025-11-25
亚虹医药涨5.10%，太平洋二个月前给出“买入”评级，目标价15.68元
每周股票复盘：亚虹医药（688176）将召开2025年第三季度业绩说明会
证券之星 · 2025-11-23
每周股票复盘：亚虹医药（688176）将召开2025年第三季度业绩说明会
亚虹医药创60日新低，太平洋二个月前给出“买入”评级，目标价15.68元
证券之星 · 2025-11-21
亚虹医药创60日新低，太平洋二个月前给出“买入”评级，目标价15.68元
【机构调研记录】汇添富基金调研亚虹医药
证券之星 · 2025-11-20
【机构调研记录】汇添富基金调研亚虹医药
亚虹医药（688176）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.31%
证券之星 · 2025-11-19
亚虹医药（688176）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.31%
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":12.37,"timestamp":1768287601000,"preClose":12.6,"halted":0,"volume":14085687,"delay":0,"changeRate":-0.0183,"floatShares":436000000,"shares":571000000,"eps":-0.6341,"marketStatus":"已收盘","change":-0.23,"latestTime":"01-13 15:00:01","open":12.67,"high":12.77,"low":12.36,"amount":176000000,"amplitude":0.0325,"askPrice":12.38,"askSize":102,"bidPrice":12.37,"bidSize":152,"shortable":0,"etf":0,"ttmEps":-0.6341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":13.86,"lowLimit":11.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":571170486,"isCdr":false,"pbRate":4.05,"roa":"--","roe":"--","epsLYR":-0.68,"committee":-0.155939,"marketValue":7065000000,"turnoverRate":0.0323,"status":1,"afterMarket":{"amount":0,"volume":0,"close":12.37,"buyVolume":0,"sellVolume":0,"time":1768289637558,"indexStatus":"已收盘 01-13 15:30:00","preClose":12.6},"floatMarketCap":5389000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2602398635","title":"每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398635?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:28","pubTimestamp":1768076889,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，亚虹医药报收于11.99元，较上周的11.51元上涨4.17%。本周，亚虹医药1月9日盘中最高价报12.24元。亚虹医药当前最新总市值68.48亿元，在化学制药板块市值排名85/150，在两市A股市值排名2758/5182。公司公告汇总江苏亚虹医药科技股份有限公司自愿披露关于APL-2401完成I期临床试验首例受试者入组公告。该药物已纳入国家药监局“30日通道”，并在获批后15个工作日内实现首例给药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2601845398","title":"亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845398","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601845398?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:24","pubTimestamp":1767882261,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，亚虹医药报收于11.78元，较前一交易日上涨1.55%，最新总市值为67.28亿元。该股当日开盘11.6元，最高11.91元，最低11.52元，成交额达1.42亿元，换手率为2.77%。公司近日发布公告称，其自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验已完成首例受试者入组。APL-2401为高选择性FGFR2/3双靶点小分子抑制剂，临床前研究显示其在多种FGFR2/3异常模型中具有优异疗效和更宽安全窗。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2601594773","title":"亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601594773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601594773?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:09","pubTimestamp":1767859754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，公司自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验完成首例受试者入组。APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3(FGFR2/3)双靶点小分子抑制剂，有望为晚期实体瘤(例如：尿路上皮癌、胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤)患者提供一种新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2600003991","title":"每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2600003991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600003991?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:11","pubTimestamp":1767298269,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚虹医药报收于11.06元，较上周的11.36元下跌2.64%。本周，亚虹医药12月22日盘中最高价报11.62元。PL-2401为全球同步研发的1类创新药，已纳入国家药监局“30日通道”，仅用22个工作日获得临床试验批准，系全国首批获批项目之一。相比现有产品，PL-2401显著降低FGFR1和FGFR4相关毒副作用，临床前模型中展现宽安全窗和优异疗效，具潜在同类最佳优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2595349577","title":"股市必读：亚虹医药（688176）12月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2595349577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595349577?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:00","pubTimestamp":1767027645,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，亚虹医药报收于11.57元，上涨4.61%，换手率3.67%，成交量15.98万手，成交额1.83亿元。来自机构调研要点：PL-2401成为全国首批通过“30日通道”获批的创新药项目之一，仅用22个工作日获临床试验批准。PL-2401为全球同步研发的1类创新药，已获国家药监局批准开展在FGFR2/3驱动的晚期实体瘤患者中的I期临床试验，仅用22个工作日完成审批，成为全国首批纳入“30日通道”的项目之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000000567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2594478222","title":"每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594478222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594478222?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:44","pubTimestamp":1766868248,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚虹医药报收于11.06元，较上周的11.36元下跌2.64%。本周，亚虹医药12月22日盘中最高价报11.62元。本周关注点公司公告汇总：APLD-2304向欧盟提交CE医疗器械注册申请并获接收。目前尚需通过欧盟公告机构审评审批方可上市销售。陈宝华先生自取得证明之日起正式履行董事会秘书职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2593129954","title":"亚虹医药：陈宝华正式履职董事会秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593129954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593129954?lang=zh_cn&edition=full","pubTime":"2025-12-21 16:20","pubTimestamp":1766305242,"startTime":"0","endTime":"0","summary":"亚虹医药(688176.SH)公告称，近日，陈宝华参加了上海证券交易所科创板上市公司董事会秘书任职培训，并已取得了董事会秘书任职培训证明。公司已按相关规定将陈宝华的董事会秘书任职资格提交上海证券交易所备案。陈宝华自取得科创板上市公司董事会秘书任职培训证明之日起正式履行公司董事会秘书职责。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100002839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2593260651","title":"亚虹医药：APLD-2304申报欧洲医疗器械注册获接收","url":"https://stock-news.laohu8.com/highlight/detail?id=2593260651","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593260651?lang=zh_cn&edition=full","pubTime":"2025-12-21 15:51","pubTimestamp":1766303467,"startTime":"0","endTime":"0","summary":"亚虹医药(688176.SH)公告称，公司产品APLD-2304向欧盟公告机构提交了医疗器械注册申请材料，并获得欧盟公告机构接收，后续尚需通过欧盟公告机构的审评、审批后方可上市销售。APLD-2304 是公司针对膀胱癌诊断及随访监测的使用场景和需求，研发的世界上首款便携式一次性蓝光膀胱软镜。由于产品的研发周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100001531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","09997","09996","BK1574","BK0239","688176","BK1222","BK1100","BK1583"],"gpt_icon":0},{"id":"2592962161","title":"亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592962161","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592962161?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:42","pubTimestamp":1765957364,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告，公司收到国家药品监督管理局(NMPA)签发的《药物临床试验批准通知书》，公司APL-2401(药物名称为ASN-8639片)在FGFR2/3驱动的晚期实体瘤患者中开展I期临床试验申请获得批准。公告显示，APL-2401为全球同步研发的1类创新药，其国际多中心临床试验设计及申报资料符合国际临床试验技术标准体系要求，成功纳入国家药监局于2025年9月12日发布的《关于优化创新药临床试验审评审批有关事项的公告(2025年第86号)》规定的“30日通道”，并以仅22个工作日获得批准，成为全国首批获得此项新政审批通过的项目之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2590650895","title":"亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590650895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590650895?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:01","pubTimestamp":1765537295,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月12日亚虹医药发布公告称安信基金、中信建投基金、西南证券、信达证券于2025年12月12日调研我司。PL-1401是公司通过自主研究并发现其全新作用机制用于治疗自身免疫疾病的口服创新药物。UC的炎症性质可导致持续性肠损伤，并增加住院、手术和结直肠癌的风险。PL-2302的临床前研究结果入选2024年美国癌症研究协会年会，并以壁报形式公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200031225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","601066","688176","BK0239"],"gpt_icon":0},{"id":"2590540501","title":"【机构调研记录】淳厚基金调研亚虹医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2590540501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590540501?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:11","pubTimestamp":1765498290,"startTime":"0","endTime":"0","summary":"淳厚基金成立于2018年，截至目前，资产管理规模199.12亿元，排名125/211；资产管理规模199.11亿元，排名107/211；管理公募基金数33只，排名122/211；旗下公募基金经理10人，排名107/211。旗下最近一年表现最佳的公募基金产品为淳厚信睿混合A，最新单位净值为3.46，近一年增长67.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200004442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2590916735","title":"亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590916735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590916735?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:44","pubTimestamp":1765446286,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月11日亚虹医药发布公告称国信证券资管、中银资管、信达证券、长盛基金、神农投资、希瓦资产、太保资产、申万宏源、从容投资、东吴基金、财通基金、诗佑私募基金、东方红基金、兴全基金、淳厚基金、信达澳银基金于2025年12月9日调研我司。目前公司正在全力加快推进其上市审评审批工作，以期尽快获得上市批准。PL-2302的临床前研究结果入选2024年美国癌症研究协会年会，并以壁报形式公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100028554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2588125840","title":"亚虹医药(688176.SH)在ECC发布APL-1401Ⅰb期临床试验相关数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2588125840","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588125840?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:46","pubTimestamp":1764755172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，近日，公司开展的APL-1401用于治疗中重度活动性溃疡性结肠炎的Ⅰb期临床试验结果入选第19届欧洲结直肠大会(ECC)，并以壁报形式发布该研究的临床数据。APL-1401是公司通过自主研究并发现其全新作用机制用于治疗自身免疫疾病的口服创新药物。APL-1401是一种强效、选择性的多巴胺β-羟化酶(DBH)抑制剂，通过抑制DBH，从而阻断了多巴胺(DA)合成去甲肾上腺素(NE)唯一的催化酶，导致DA升高、NE降低，使肠道免疫稳态恢复正常。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ECC","BK0239","688176"],"gpt_icon":0},{"id":"2586738733","title":"亚虹医药（688176）披露变更签字注册会计师公告，11月28日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738733?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:40","pubTimestamp":1764340841,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，亚虹医药报收于10.18元，较前一交易日上涨0.1%，最新总市值为58.15亿元。该股当日开盘10.17元，最高10.21元，最低10.07元，成交额达3091.63万元，换手率为0.7%。公司近日发布公告称，原聘任的2025年度审计机构立信会计师事务所签字注册会计师为王法亮先生和杨成艳女士。其不存在影响独立性的情形，近三年未受处罚或处分。本次变更不影响公司2025年度财务报告审计工作的正常进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800041018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2586244166","title":"亚虹医药：11月27日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2586244166","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586244166?lang=zh_cn&edition=full","pubTime":"2025-11-27 19:01","pubTimestamp":1764241317,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月27日亚虹医药发布公告称公司于2025年11月27日召开业绩说明会。问11、亚虹医药近年营收持续大幅增长，但长期处于未盈利状态。问6截止到今天11月27日，亚虹医药目前股东人数有多少？惠及广大膀胱癌患者。亚虹医药2025年三季报显示，前三季度公司主营收入2.16亿元，同比上升55.74%；归母净利润-2.49亿元，同比上升8.08%；扣非净利润-2.67亿元，同比上升6.69%；其中2025年第三季度，公司单季度主营收入8617.08万元，同比上升47.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700030003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2586473854","title":"亚虹医药涨5.10%，太平洋二个月前给出“买入”评级，目标价15.68元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473854?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:33","pubTimestamp":1764056010,"startTime":"0","endTime":"0","summary":"今日亚虹医药涨5.10%，收盘报10.3元。2025年9月3日，太平洋研究员周豫,戎晓婕发布了对亚虹医药的研报《收入同比增长62%，APL-1702国内审评进展顺利》，该研报对亚虹医药给出“买入”评级，认为其目标价为15.68元，现价距离目标价尚有52.23%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为73.22%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的唐寅灏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","601099"],"gpt_icon":0},{"id":"2585106960","title":"每周股票复盘：亚虹医药（688176）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106960","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106960?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:45","pubTimestamp":1763844311,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，亚虹医药报收于9.5元，较上周的10.16元下跌6.5%。本周，亚虹医药11月18日盘中最高价报10.43元。本周关注点公司公告汇总：江苏亚虹医药科技股份有限公司将于2025年11月27日召开2025年第三季度业绩说明会。业绩披露要点：公司将介绍2025年第三季度经营成果及财务状况。投资者可于11月20日至26日通过上证路演中心或公司邮箱securities@asieris.cn提前提问，说明会期间公司将对普遍关注的问题进行回应。会议结束后可通过上证路演中心查看召开情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2585819772","title":"亚虹医药创60日新低，太平洋二个月前给出“买入”评级，目标价15.68元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585819772","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585819772?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:44","pubTimestamp":1763711084,"startTime":"0","endTime":"0","summary":"今日亚虹医药创60日新低，收盘报9.5元。2025年9月3日，太平洋研究员周豫,戎晓婕发布了对亚虹医药的研报《收入同比增长62%，APL-1702国内审评进展顺利》，该研报对亚虹医药给出“买入”评级，认为其目标价为15.68元，研报发布时股价为12.35元，预期涨幅为26.96%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的唐寅灏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","601099"],"gpt_icon":0},{"id":"2584897243","title":"【机构调研记录】汇添富基金调研亚虹医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2584897243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584897243?lang=zh_cn&edition=full","pubTime":"2025-11-20 08:05","pubTimestamp":1763597121,"startTime":"0","endTime":"0","summary":"汇添富基金成立于2005年，截至目前，资产管理规模10703.88亿元，排名9/211；资产管理规模6520.91亿元，排名8/211；管理公募基金数765只，排名6/211；旗下公募基金经理96人，排名8/211。旗下最近一年表现最佳的公募基金产品为汇添富香港优势精选混合A，最新单位净值为1.4，近一年增长126.78%。旗下最新募集公募基金产品为汇添富稳颐优选债券A，类型为债券型-混合二级，集中认购期2025年11月3日至2025年11月21日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000003935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2584491470","title":"亚虹医药（688176）披露召开2025年第三季度业绩说明会，11月19日股价下跌3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584491470","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584491470?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:34","pubTimestamp":1763544893,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，亚虹医药报收于9.94元，较前一交易日下跌3.31%，最新总市值为56.77亿元。近日，江苏亚虹医药科技股份有限公司发布公告称，公司将于2025年11月27日13:00-14:45通过上证路演中心召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。投资者可于11月20日至26日通过上证路演中心或公司邮箱securities@asieris.cn提前提问，说明会期间公司将对普遍关注的问题进行回应。会议结束后可通过上证路演中心查看召开情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900028279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768306602343,"stockEarnings":[{"period":"1week","weight":0.0742},{"period":"1month","weight":0.2426},{"period":"3month","weight":0.2714},{"period":"6month","weight":0.1372},{"period":"1year","weight":0.9687},{"period":"ytd","weight":0.0947}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25192人(较上一季度减少1.06%)","perCapita":"17294股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57117万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}